TAK May 2024 12.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:46AM EDT
| Previous close | 0.9000 |
| Open | 0.8000 |
| Bid | 0.7000 |
| Ask | 0.8500 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.8000 - 0.8100 |
| Contract range | N/A |
| Volume | |
| Open interest | 417 |
Investor's Business DailyCatalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
Business WireTakeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
OSAKA, Japan, May 09, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.
GuruFocus.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
© 2024 Yahoo. All rights reserved.